Development of a method to separate lipoprotein-bound and lipoprotein- depleted tissue factor pathway inhibitor. Measurement of free tissue factor pathway inhibitor activity

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 7, 1998, Pages 637-643

  Bridey, F ^a   Lacombe, C ^a   Sustendal, L ^a   Moatti, D ^a   Combe, F ^a   Mammes O ^a   De Prost, D ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Assay; Free; Heparin; TFPI; Tissue factor pathway inhibitor

Indexed keywords

HEPARIN; LIPOPROTEIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; HEMOSTASIS; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; ULTRACENTRIFUGATION;

EID: 0031742302     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199810000-00011     Document Type: Article

References (15)

1. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
2. Sandset PM, Abildgaard U. Extrinsic pathway inhibitor - the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21: 219-239.
3. Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997; 78: 759-764.
4. Sandset PM, Bendz B. Tissue factor pathway inhibitor: clinical deficiency states. Thromb Haemost 1997; 78: 467-470.
5. Sandset PM. Tissue factor pathway inhibitor (TFPI) - an update. Haemostasis 1996; 26: 154-165.
6. Novotny WF. Tissue factor pathway inhibitor. Semin Thromb Hemost 1994; 20: 101-108.
7. Lindahl AK, Abildgaard U, Larsen ML, Staalesen R, Hammer AKG, Sandset PM, et al. Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Thromb Res 1991; 62: 607-614.
8. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Odegaard U. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coag Fibrinol 1991; 2: 425-433.
9. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 1981; 22: 339-358.
10. Moor E, Hamsten A, Karpe F, Bavenholm P, Blomback M, Silveira A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemost 1994; 71: 707-712.
11. Bara L, Bloch ML, Zitoun D, Samama M, Collignon F, Frydman A, et al. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-452.
12. Kokawa T, Abumiya T, Kimura T, Haradashiba M, Koh H, Tsushima M, et al. Tissue factor pathway inhibitor activity in human plasma - measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscler Thromb Vasc Biol 1995; 15: 504-510.
13. Lesnik P, Vonica A, Guerin M, Moreau M, Chapman J. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb 1993; 13: 1066-1075.
14. Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hanssen TA, Nordoy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb Vasc Biol 1995; 15: 879-885.
15. Ettelaie C, James NJ, Wilbourn B, Adam JM, Naseem KM, Bruckdorfer KR. The mechanism of inhibition of factor III (thromboplastin) activity by apolipoprotein B-100 - protein-protein interactions. Arterioscler Thromb Vasc Biol 1996; 16: 639-647.